Monoclonal Antibody Cocktail: Future Trend for the Treatment of Canine Atopic Dermatitis?
Monoclonal Antibodies Revolutionize Pruritic Skin Disease Treatment in Dogs
🐕Over the last few years, veterinary research has made enormous progress toward understanding the cytokine profile in atopic dogs. This understanding helped laid the foundation for the development of monoclonal antibodies that completely changed the scenario of pruritic skin diseases.
IL-31 cytokine
💊 IL-31 cytokine has been identified as one of the key cytokines responsible for pruritus in dogs. In addition to the IL-31 pathways, many other cytokines have been thought to be involved in allergic pruritus and/or inflammatory cascade: IL-4, IL-6, IL-13, IL-17, etc.
Endo-phenotypes in AD
🧬 Apart from the cytokine profile, veterinary scientists have been discussing the concept of breed-specific endo-phenotypes in AD. As shown recently in its human disease counterpart, canine AD is a heterogeneous disease that potentially has a variety of clinical and molecular phenotypes.
Genomics
💡 Advancements in genomics will enable the characterization of various breed-specific clinical phenotypes. In the near future, new biologically active agents may become available, providing even more targeted treatments. Instead of relying solely on a single monoclonal antibody, the use of cocktails of monoclonal antibodies may become available for veterinary prescription
📖 References:
➡️ Mazier et al Altered plasma cytokines in dogs with atopic dermatitis Vet Dermatology 2022
➡️ Bieber et al. Clinical phenotypes and endophenotypes of atopic dermatitis J Allergy Immunol 2017 https://pubmed.ncbi.nlm.nih.gov/28390478/
Image credits: Freepik
